Gene
PIK3R2
PIK3R2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Actionable biomarkers (1), Trial mentions (3), Target-disease associations (259), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention PIK3R2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
PIK3R2 has 3 trial mentions across 3 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 6 of 11,460 | 0.05% |
| 2022 | 0 of 8,285 | 0.00% | 12 of 13,598 | 0.09% |
| 2021 | 0 of 8,692 | 0.00% | 7 of 15,045 | 0.05% |
| 2020 | 0 of 7,640 | 0.00% | 6 of 14,459 | 0.04% |
| 2019 | 1 of 7,300 | 0.01% | 8 of 12,159 | 0.07% |
| 2018 | 0 of 6,927 | 0.00% | 10 of 11,854 | 0.08% |
| 2017 | 0 of 6,558 | 0.00% | 8 of 11,595 | 0.07% |
Showing 10 of 37 years.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| PIK3R2 (A171V,N561D) | Mtor Inhibitors | response-associated | endometrial carcinoma | Cancer Genome Interpreter |
Trial mentions (3)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04192981 | Trial eligibility (AACT) |
| NCT02549989 | Trial eligibility (AACT) |
| NCT02065687 | Trial outcomes (AACT) |
Target-disease associations (259)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alzheimer disease | nervous system disease | crispr screen |
| Anal Squamous Cell Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Atypical Endometrial Hyperplasia | cancer or benign tumor | Cancer Gene Census |
| Atypical Meningioma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 259 associations.
Vendor sourcing (26)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v4.1.0 dataset. Predicted Consequence/Location: The variant is located in a mutational hot spot and/or well-establi... | View ClinVar record SCV002012148.2 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1117G>A (p.G373R) alteration is located in exon 10 (coding exon 9) of the PIK3R2 gene. This alteration results from a G to A substitution at nucleotide... | View ClinVar record SCV000244101.9 |
| Centre Hospitalier Universitaire de Nantes | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001334377.1 |
| DASA (Brazil) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | NM_005027.4(PIK3R2):c.1942G>A (p.Glu648Lys) is a missense variant that results in the substitution of glutamic acid with lysine. This variant is rare in popu... | View ClinVar record SCV007662132.2 |
| ELI LILLY & Co | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Patients must have recurrent or persistent endometrial carcinoma Patients with the following histologic epithelial cell types are eligible: endometrioid... | View trial NCT02549989 |
Showing 5 of 26 sourcing records.
Trial-cited literature (100)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy. | Cancers | 2023 | 89 |
| Hot Spots for the Use of Intranasal Insulin: Cerebral Ischemia, Brain Injury, Diabetes Mellitus, Endocrine Disorders and Postoperative Delirium. | International journal of molecular sciences | 2023 | 31 |
| HGFAC is a ChREBP-regulated hepatokine that enhances glucose and lipid homeostasis. | JCI insight | 2023 | 25 |
| Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer. | Breast cancer research and treatment | 2023 | 9 |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell reports. Medicine | 2023 | 8 |
Showing 5 of 100 papers.
Protein variant mentions (13)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A727T | 1 | 2015 | PMID 25741868 |
| p.E274A | 1 | 2015 | PMID 25741868 |
| p.F352L | 1 | 2015 | PMID 25741868 |
| p.G373R | 2 | 2015 to 2016 | PMID 28567303, PMID 25741868 |
| p.H698P | 1 | 2015 | PMID 25741868 |
Showing 5 of 13 variants.
Literature-extracted relations (3)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| CURCUMIN | Chemical | negative_correlate |
Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. | 2011 |
| lipids | Chemical | associate |
Co-compartmentalization of MAP kinases and cytosolic phospholipase A2 at cytoplasmic arachidonate-rich lipid bodies. | 1998 |
| Anemia, Aplastic | Disease | associate |
Identification of novel microRNA signatures linked to acquired aplastic anemia. | 2015 |
Organizations publishing (119)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 6 | 2013 to 2023 |
| Beth Israel Deaconess Medical Center | Hospital | 4 | 1998 to 2023 |
| Harvard Medical School | Academic | 4 | 1998 to 2018 |
| University of Toronto | Academic | 4 | 2016 to 2020 |
| Central South University | Academic | 3 | 2018 to 2023 |
Showing 5 of 119 organizations.
Where PIK3R2 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- measurement
- nervous system disease
- phenotype
- respiratory or thoracic disease
222 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, assay-provider ledger, and human sample screening reference.